English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

On February 13, 2007, the Food and Drug Administration (FDA) released a public health notification on RotaTeq (Live, Oral, Pentavalent Vaccine—Merck and Co.) and intussusception.1 The report stated that there were 28 cases of intussusception in the ongoing post-marketing surveillance. Also, this notification stated that the purpose of this notification was to encourage the reporting of additional cases and to remind providers that “intussusception is a

Rotavirus Vaccine and Intussusception